ARK Investment Management LLC Sells 714 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ARK Investment Management LLC cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,151 shares of the biopharmaceutical company’s stock after selling 714 shares during the quarter. ARK Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $15,928,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. International Assets Investment Management LLC grew its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares during the period. Capital International Investors lifted its stake in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares during the period. TD Asset Management Inc increased its holdings in Regeneron Pharmaceuticals by 162.9% during the first quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after buying an additional 166,998 shares during the last quarter. Finally, Swedbank AB bought a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $129,257,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN opened at $824.48 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The business has a fifty day moving average of $1,035.92 and a 200 day moving average of $1,038.36. Regeneron Pharmaceuticals, Inc. has a 52-week low of $783.57 and a 52-week high of $1,211.20. The stock has a market cap of $90.89 billion, a P/E ratio of 20.40, a PEG ratio of 3.17 and a beta of 0.15.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.48% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

REGN has been the topic of a number of analyst reports. JPMorgan Chase & Co. lowered their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Evercore ISI cut their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Finally, BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,092.62.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.